These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12725017)

  • 1. [Current concepts of pharmacological treatment in schizophrenia].
    Jarema M
    Psychiatr Pol; 2002; 36(6):857-68. PubMed ID: 12725017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Longterm treatment of schizophrenia].
    Pajonk VF
    MMW Fortschr Med; 2006 Jan; 148(4):35-8. PubMed ID: 16502798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
    Leucht S; Heres S
    J Clin Psychiatry; 2006; 67 Suppl 5():3-8. PubMed ID: 16822090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Subjective aspects of psychopharmacology in schizophrenia].
    Murawiec S
    Psychiatr Pol; 1999; 33(1):25-35. PubMed ID: 10786213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
    Buckley PF; Stahl SM
    Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of schizophrenia with "atypical antipsychotic drugs". Quality of life as a measure of treatment success].
    Krankenpfl J; 2002; 40(7-9):230-1. PubMed ID: 12514869
    [No Abstract]   [Full Text] [Related]  

  • 10. Recommendations from treatment guidelines for schizophrenia regarding monitoring of side effects of antipsychotics: brief review.
    Kozumplik O; Uzun S
    Psychiatr Danub; 2009 Mar; 21(1):95-8. PubMed ID: 19270630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.
    Lambert M; Schimmelmann BG; Karow A; Naber D
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S181-90. PubMed ID: 14677077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].
    Mercier C; Bret P; Bret MC; Queuille E
    Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables.
    Stanković Z; Britvić D; Vuković O; Ille T
    Psychiatr Danub; 2008 Mar; 20(1):42-52. PubMed ID: 18376330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The problem of drug compliance in schizophrenic patients].
    Albus M
    Psychiatr Prax; 1995 Nov; 22(6):221-2. PubMed ID: 8570750
    [No Abstract]   [Full Text] [Related]  

  • 15. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early detection and treatment of schizophrenia].
    Hasan A; Falkai P; Wobrock T
    MMW Fortschr Med; 2010 Mar; 152(9):53-5. PubMed ID: 20384099
    [No Abstract]   [Full Text] [Related]  

  • 17. [Psychological conditions of patient's decision to break off the treatment with atypical neuroleptic: a case study].
    Murawiec S
    Psychiatr Pol; 2000; 34(2):289-98. PubMed ID: 10974942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
    Benoit M; Pon J; Zimmermann MA
    Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
    [No Abstract]   [Full Text] [Related]  

  • 19. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). What are the limiting factors in resort to an APAP and how to overcome them].
    Canceil O; Limosin F; Passerieux C
    Encephale; 2009 Jan; Suppl 3():S101-7. PubMed ID: 19268178
    [No Abstract]   [Full Text] [Related]  

  • 20. [Better prognosis due to new treatment approaches. Therapy of schizophrenia in 2002].
    Janssen B; Gaebel W
    MMW Fortschr Med; 2002 May; Suppl 2():72-6, 78. PubMed ID: 12070858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.